Display options
Cite
O'Bryant SE, Lista S, Rissman RA, et al. Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimers Dement (Amst). 2015;3:27-34doi: 10.1016/j.dadm.2015.12.003.
O'Bryant, S. E., Lista, S., Rissman, R. A., Edwards, M., Zhang, F., Hall, J., Zetterberg, H., Lovestone, S., Gupta, V., Graff-Radford, N., Martins, R., Jeromin, A., Waring, S., Oh, E., Kling, M., Baker, L. D., & Hampel, H. (2016). Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimer's & dementia (Amsterdam, Netherlands), 327-34. https://doi.org/10.1016/j.dadm.2015.12.003
O'Bryant, Sid E, et al. "Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 3 (2016): 27-34. doi: https://doi.org/10.1016/j.dadm.2015.12.003
O'Bryant SE, Lista S, Rissman RA, Edwards M, Zhang F, Hall J, Zetterberg H, Lovestone S, Gupta V, Graff-Radford N, Martins R, Jeromin A, Waring S, Oh E, Kling M, Baker LD, Hampel H. Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimers Dement (Amst). 2015 Dec 29;3:27-34. doi: 10.1016/j.dadm.2015.12.003. eCollection 2016. PMID: 27019866; PMCID: PMC4802360.
Copy Download .nbib Format: NLM
Share it on

Alzheimers Dement (Amst). 2015 Dec 29;3:27-34. doi: 10.1016/j.dadm.2015.12.003. eCollection 2016.

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges.

Alzheimer's & dementia (Amsterdam, Netherlands)

Sid E O'Bryant, Simone Lista, Robert A Rissman, Melissa Edwards, Fan Zhang, James Hall, Henrik Zetterberg, Simon Lovestone, Veer Gupta, Neill Graff-Radford, Ralph Martins, Andreas Jeromin, Stephen Waring, Esther Oh, Mitchel Kling, Laura D Baker, Harald Hampel

Affiliations

  1. Institute for Healthy Aging, Center for Alzheimer's & Neurodegenerative Disease Research, University of North Texas Health Science Center, TX, USA.
  2. AXA Research Fund & UPMC Chair, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) & Institut du Cerveau et de la Moelle épinière (ICM), Département de Neurologie, Hôpital de la Pitié-Salpétrière, Paris, France.
  3. Alzheimer's Disease Cooperative Study, Department of Neurosciences, UCSD School of Medicine, La Jolla, CA, USA.
  4. Department of Psychology, University of North Texas, Denton, TX, USA.
  5. Department of Molecular and Medical Genetics, University of North Texas Health Science Center, Fort Worth, TX, USA.
  6. Institute for Healthy Aging, Center for Alzheimer's & Neurodegenerative Disease Research, University of North Texas Health Science Center, TX, USA; Department of Psychiatry, University of North Texas Health Science Center, Fort Worth, TX, USA.
  7. Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; UCL Institute of Neurology, London, UK.
  8. Department of Psychiatry, University of Oxford, Oxford, UK.
  9. Center of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Faculty of Health, Engineering and Sciences, Edith Cowan University, Joondalup, WA, Australia.
  10. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  11. Quanterix Corp., Lexington, MA, USA.
  12. Essentia Institute of Rural Health, Duluth, MN, USA; Texas Alzheimer's Research and Care Consortium, TX, USA.
  13. Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  14. Behavioral Health Service, Cpl. Michael J. Crescenz VA Medical Center and Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  15. Department of Medicine, Internal Medicine (Geriatrics), Wake Forest School of Medicine, Winston Salem, NC, USA.

PMID: 27019866 PMCID: PMC4802360 DOI: 10.1016/j.dadm.2015.12.003

Abstract

INTRODUCTION: This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms.

METHODS: Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots.

RESULTS: On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared >50% of the variance across blood fractions (serum amyloid A R(2) = 0.99, interleukin (IL)10 R(2) = 0.95, fatty acid-binding protein (FABP) R(2) = 0.94, I309 R(2) = 0.94, IL-5 R(2) = 0.94, IL-6 R(2) = 0.94, eotaxin3 R(2) = 0.91, IL-18 R(2) = 0.87, soluble tumor necrosis factor receptor 1 R(2) = 0.85, and pancreatic polypeptide R(2) = 0.81). When examining protein concentrations across platforms, only five markers shared >50% of the variance (beta 2 microglobulin R(2) = 0.92, IL-18 R(2) = 0.80, factor VII R(2) = 0.78, CRP R(2) = 0.74, and FABP R(2) = 0.70).

DISCUSSION: The current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers.

Keywords: Alzheimer's disease; Biomarker discovery; Blood; Diagnostics; Meso Scale Discovery; Multiplex assay platform; Plasma; Preanalytic processing; Proteins; Rules Based Medicine; Serum; Standardization

References

  1. Alzheimers Dement. 2014 Jan;10(1):115-31 - PubMed
  2. J Alzheimers Dis. 2013;34(4):841-9 - PubMed
  3. Neuroimage. 2012 Jan 2;59(1):212-7 - PubMed
  4. J Alzheimers Dis. 2012;30(2):323-36 - PubMed
  5. Arch Neurol. 2010 Sep;67(9):1077-81 - PubMed
  6. Nature. 2014 Jan 30;505(7485):612-3 - PubMed
  7. Alzheimers Dement. 2014 Jan;10(1):109-14 - PubMed
  8. Ann N Y Acad Sci. 2009 Oct;1180:56-67 - PubMed
  9. Prog Neurobiol. 2013 Feb-Mar;101-102:18-34 - PubMed
  10. PLoS Med. 2005 Aug;2(8):e124 - PubMed
  11. Nat Genet. 2009 Oct;41(10):1088-93 - PubMed
  12. J Alzheimers Dis. 2014;42(4):1325-35 - PubMed
  13. Neurology. 2012 Aug 28;79(9):897-905 - PubMed
  14. Nat Med. 2007 Nov;13(11):1359-62 - PubMed
  15. Dement Geriatr Cogn Disord. 2011;32(1):55-62 - PubMed
  16. Int J Alzheimers Dis. 2010 Jul 15;2010:null - PubMed
  17. Alzheimers Dement. 2014 Nov;10 (6):724-34 - PubMed
  18. Arch Neurol. 2012 Oct;69(10):1318-25 - PubMed
  19. Prog Neurobiol. 2013 Feb-Mar;101-102:1-17 - PubMed
  20. Nat Rev Drug Discov. 2011 Aug 31;10(9):712 - PubMed
  21. J Neuroimmunol. 2010 Mar 30;220(1-2):114-9 - PubMed
  22. Mol Psychiatry. 2014 Jan;19(1):88-98 - PubMed
  23. Alzheimers Dement. 2015 May;11(5):549-60 - PubMed
  24. PLoS One. 2011;6(12):e28092 - PubMed
  25. J Alzheimers Dis. 2013;34(3):701-6 - PubMed
  26. Neurology. 1984 Jul;34(7):939-44 - PubMed
  27. Thromb Res. 2007;120(6):811-4 - PubMed

Publication Types

Grant support